You are here: Industry Insights > aspirin

News List

Acetaminophen API Price and Acetaminophen sodium manufacturers in China PharmaSources
July 13, 2021
Acetaminophen is a drug used to treat moderate pain and fever in some conditions.
Aspirin is linked with increased risk of heart failure WorldPharmaNews
November 24, 2021
Aspirin use is associated with a 26% raised risk of heart failure in people with at least one predisposing factor for the condition. That’s the finding of a study published today in ESC Heart Failure, a journal of the European Society of Cardiology (ESC).
No survival benefit from aspirin in COVID-19 patients pharmatimes
June 10, 2021
Findings of the UK RECOVERY trial show that use of aspirin in the hope of reducing blood clotting in patients hospitalised with COVID-19 does not have any impact on survival.
Aspirin may decrease ICU admission and death in COVID-19 patients europeanpharmaceuticalreview
March 18, 2021
In a new study, low dose aspirin reduced risk of mechanical ventilation, ICU admission and in-hospital mortality by over 40 percent each.
PLx Pharma Receives FDA Approval of SNDAs for Two VAZALORE Dosages americanpharmaceuticalreview
March 04, 2021
PLx Pharma announced the U.S. Food and Drug Administration (FDA) approved supplemental new drug applications (sNDAs) for its lead products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as VAZALORE), the first novel, liquid-filled aspirin ...
Granules India gets USFDA approval for OTC Acetaminophen, Aspirin and Caffeine Tablets expresspharma
February 25, 2021
Granules India announced that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA) for Acetaminophen, Aspirin and Caffeine Tablets USP, 250 mg/250 mg/65 mg (OTC).
AZ’s Brilinta reduced rate of stroke and death in high-risk subgroup pharmatimes
November 19, 2020
AstraZeneca’s P2Y12 receptor antagonist Brilinta reduced the rate of stroke and death in a prespecified, high-risk subgroup, according to new analysis of the phase III THALES trial.
Brilinta Approved to Reduce Stroke Risk americanpharmaceuticalreview
November 17, 2020
AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk ...
UK study will evaluate aspirin as a potential COVID-19 treatment pharmatimes
November 11, 2020
Researchers from the UK’s RECOVERY study will evaluate the standard painkiller aspirin as a potential treatment for COVID-19 patients.
Trial in Britain to assess aspirin as potential COVID-19 drug expresspharma
November 09, 2020
The scientists behind the RECOVERY trial, which is looking into a range of potential treatments for COVID-19, said it would include the drug, which is commonly used as a blood thinner.

Previous page 1 2 3 4 5 6 Next page